



ÚOCHB AV  
IOCB PRAGUE

6th Advanced in silico Drug Design workshop/challenge 2023



# Fantastic Natural Products and Where to Find Them

Dr. Olena Mokshyna | 31.01.2023



IOCB Prague



## Tomáš Pluskal Group

### Biochemistry of Plant Specialized Metabolites

Experiments  Computations  
for  bioactive molecules discovery


  
**MZmine 3**

 **transXpress**


# Natural Products (NPs): what are they?

Any compound produced by **living organisms**


## Primary metabolites



Lactic acid




Valine




Lactose

No pharmacological activity!


## Secondary metabolites




(R)-carvone



Strychnine  
Biologically active



Nicotine






# Plants with unusual properties become first medicines



Sumerian clay  
tablet,  
c. 3000 BC



Ebers papyrus, Ancient  
Egypt  
c. 1550 BC




Arabic Dioscorides,  
1224




*Papaver somniferum*


## Since then, NPs became a Prominent Source of Drugs



## Salicin



## Aspirin




# Taxol

## Anticancer



***Taxus brevifolia*,**  
the Pacific yew



## Artemisinin




***Artemisia annua*,**  
sweet wormwood


# Drugs from bacterial and fungal NPs




## *Penicillium* fungus



## Penicillin G, antibiotic




***Tolypocladium inflatum***  
fungus



## Ciclosporin, immunosuppressant




## *Streptomyces hygroscopus*



## Rapamycin, immunosuppressant

# Many modern drugs originate from natural products (NP)



>30%


All small-molecule drugs 1981-2019

**Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019**

David J. Newman\* and Gordon M. Cragg  
*J. Nat. Prod.* 2020, 83, 3, 770–803, [10.1021/acs.jnatprod.9b01285](https://doi.org/10.1021/acs.jnatprod.9b01285)



# NPs exhibit unique diversity



Chassagne, F., Cabanac, G., Hubert, G. *et al.* The landscape of natural product diversity and their pharmacological relevance from a focus on the *Dictionary of Natural Products*<sup>®</sup>. *Phytochem Rev* **18**, 601–622 (2019).

<https://doi.org/10.1007/s11101-019-09606-2>





# NPs Structures differ from those of Synthetic Drugs

“Plants don’t run”


“Natural products differ from synthetic molecules by having evolutionary history”

Structurally more complex:


- Higher molecular mass
- More  $sp^3$  C
- Less N & halogens
- More H-bond acceptors & donors
- Lower logP
- Greater rigidity but “more 3D”

primarily recognized as **privileged structures** to interact with protein drug targets

Synthetic drugs




Apixaban



Ibrutinib

NP and NP-derived drugs



Voclosporin



# Decline of NP in pharma Science

## Drug Discovery and Natural Products: End of an Era or an Endless Frontier?

JESSE W.-H. LI AND JOHN C. VEDERAS [DOI: 10.1126/science.1168243](https://doi.org/10.1126/science.1168243)


**Table 1** Big/medium Pharma Companies which have currently ceased (between 2000 and 2013) or are still bioprospecting

| Arrest               | Continuation |
|----------------------|--------------|
| Abbott               | Dabur        |
| Astellas             | Eisai        |
| Bayer                | Novartis     |
| Boehringer Ingelheim | Otsuka       |
| Bristol-Myers Squibb | Pierre Fabre |
| Daiichi Sankyo       | Piramal      |
| Eli Lilly            |              |
| GlaxoSmithKline      |              |
| Johnson and Johnson  |              |
| Kyowa Hakko          |              |




37 new drugs approved by  
FDA  
2022

## Diagnosing the decline in pharmaceutical R&D efficiency


[Jack W. Scannell](#) , [Alex Blanckley](#), [Helen Boldon](#) & [Brian Warrington](#)

[Nature Reviews Drug Discovery](#) **11**, 191–200 (2012) | [Cite this article](#)


### Finding new drug got harder



2015




### Avermectin and derivatives





# Milestones in the NP-driven drug discovery





# Grind-and-find approach

doesn't work that well

And largely relies on serendipity

Dereplication:

- Time
- Money
- Repeated efforts



Not enough biological material to isolate and characterize a bioactive NP

Extraction  
Fractination


Rediscovery of already known NPs

Identification  
and annotation

Searching for biological activity in crude extracts, higher hit rates in HTS  
Single compound or extract

# Computer-assisted discovery of NPs

- Data mining into traditional medicine, papers, and plant databases
- Predicting chemical structures from microbial genomes
- Automating NP dereplication process




Saldívar-González, F. I., et al. "Natural product drug discovery in the artificial intelligence era." *Chemical Science* 13.6 (2022): 1526-1546. [10.1039/d1sc04471k](https://doi.org/10.1039/d1sc04471k)

Atanasov et al. "Natural products in drug discovery: advances and opportunities" *Nature Rev.* 20 (2021) <https://doi.org/10.1038/s41573-020-00114-z>



# NPs Databases



**CHEMnetBASE**

Dictionary of Natural  
Products  
>200k NPs



>20k NPs



>400k NPs

**WFO**

The World Flora Online



TM-MC Database of  
medicinal plants



>200k NPs

Chen, (2017) Data Resources for the Computer-Guided Discovery of Bioactive Natural Products. J. Chem. Inf. Model. 2017. [10.1021/acs.jcim.7b00341](https://doi.org/10.1021/acs.jcim.7b00341)  
Rutz, (2022) The LOTUS initiative for open knowledge management in natural products research. eLife 11:e70780. <https://doi.org/10.7554/eLife.70780>

# Genomic mining




The application potential of machine learning and genomics for understanding natural product diversity, chemistry, and therapeutic translatability. Prihoda et al. *Natural Products Reports*, 2021. <https://doi.org/10.1039/D0NP00055H>


Targeted Large-Scale Genome Mining and Candidate Prioritization for Natural Product Discovery. Malit et al. *Mar. Drugs* 2022, 20(6), 398; <https://doi.org/10.3390/md20060398>

# MS-based Untargeted Metabolomics

Chromatographic feature detection and alignment

Tandem mass spectra (MS/MS) are of crucial importance




  
**MZmine 3**

LC-IMS-MS and imaging



MS-DIAL

GC/MS



LC-MS,  
joint pathway analysis

Feature annotation



**CSI:FingerID**

Multiple kernel learning supported by  
fragmentation trees

**CASMI**

**Critical Assessment  
of Small Molecule Identification**

[www.casmi-contest.org/](http://www.casmi-contest.org/)



# Spectral data from MS as an additional tool in dereplication

Public repositories



**Mass** Spectrometry  
**I**nteractive **V**irtual **E**nvironment



## Search Parameters

Minimum Cosine Score

Minimum Matched Peaks

Parent Mass Tolerance

Fragment Mass Tolerance

Analog Search

Public Databases to Search

Populate Demo

## Spectrum Peaks

Precursor M/Z

Peaks

Enter peaks here in the follow format "mass intensity", one per line separated by white space (space or tab).

For Example:

463.381 43.591  
693.498 119.206  
694.496 42.985  
707.494 508.18  
708.512 197.117  
709.558 18.679  
723.4 43.831  
800.494 476.556

MASST Molecule

## Reporting Information

Analysis Description


Email address

GNPS Login

GNPS Password

Wang, M., Jarmusch, A.K., Vargas, F. *et al.* **Mass spectrometry searches using MASST.** *Nat Biotechnol* **38**, 23–26 (2020). <https://doi.org/10.1038/s41587-019-0375-9>

# GNPS Molecular Networking



Reproducible molecular networking of untargeted mass spectrometry data using GNPS

Allegra T. Aron et al. *Nature Protocols* volume 15, pages1954–1991 (2020) DOI

<https://doi.org/10.1038/s41596-020-0317-5>


Querying  
of nodes  
against  
public  
datasets






# Deep learning applications to accelerate metabolomic research

‘inverse problem’ of mass spectrometric molecular identification




**MSNovelist: de novo structure generation from mass spectra.** [Stravs](#) et al. *Nature Methods* volume 19, pages 865–870 (2022). <https://doi.org/10.1038/s41592-022-01486-3>

**MS2Prop: A machine learning model that directly predicts chemical properties from mass spectrometry data for novel compounds.** *bioRxiv preprint*. Voronov et al. <https://doi.org/10.1101/2022.10.09.511482>



UMAP of a sub-sample of unlabeled MS/MS spectra from GNPS. Red points – MS/MS spectra of FDA-approved drugs (not NPs)




## High-throughput functional annotation of natural products by integrated activity profiling

[Suzie K. Hight](#) et al., PNAS, **2022**

<https://doi.org/10.1073/pnas.2208458111>


# After NP identification, what's next?




- Mapping NPs in the chemical space
- De-orphanizing
- Generating *de novo* NP-inspired compounds

Saldívar-González, F. I., et al. "Natural product drug discovery in the artificial intelligence era." *Chemical Science* 13.6 (2022): 1526-1546. [10.1039/d1sc04471k](https://doi.org/10.1039/d1sc04471k)

# Chemical space of NPs







NP Navigator: A New Look at the Natural Product Chemical Space. Zabolotna et al, *J.Mol.Inf*, 2021.  
[10.1002/minf.202100068](https://doi.org/10.1002/minf.202100068)



NP-Scout: Machine Learning Approach for the Quantification and Visualization of the Natural Product-Likeness of Small Molecules. Chen et al. *Biomolecules*. 2019 Feb; 9(2): 43.  
[10.3390/biom9020043](https://doi.org/10.3390/biom9020043)

**Natural Product-Likeness**

synthetic molecules    natural products




**NP-Scout**

Identification and visualization of natural product-likeness





# Identifying scaffolds for further structural modifications

 **Scaffold Hunter**



Open-Source Cheminformatics  
and Machine Learning

**rdScaffoldNetwork**  
[rdkit.Chem.Scaffolds](https://rdkit.Chem.Scaffolds)



**Design and Synthesis of Natural Product Inspired Libraries  
Based on the Three-Dimensional (3D) Cedrane Scaffold:  
Toward the Exploration of 3D Biological Space**

Tajabadi et al, *J. Med. Chem.* 2018

<https://doi.org/10.1021/acs.jmedchem.8b00194>

# Pharmacophores & NPs

Identification of natural inhibitors of *Trypanosoma brucei* Glyceraldehyde-3-phosphate-dehydrogenase (TbGAPDH)

Human African trypanosomiasis (HAT), or “sleeping sickness”

4803 NPs from MEGx database

3 structures (PDB-IDs: 2X0N, 3IDS and 1GYF)

4 pharmacophore models by MOE

Docking


Experimental testing

**5 cmpds** w/ >50 % inhibition at 50  $\mu$ M

F. C. Herrmann, M. Lenz, J. Jose, M. Kaiser, R. Brun, T. J.

Schmidt, *Molecules* 2015, 20, 16154–16169.

[doi.org/10.3390/molecules200916154](https://doi.org/10.3390/molecules200916154)



Pharmacophore models by LigandScout

Applications of the Pharmacophore Concept in Natural Product inspired Drug Design

Seidel et al. *J.Mol.Inf.*, 2020.

<https://doi.org/10.1002/minf.202000059>


# More successful examples of NP screening

DOI: 10.1002/minf.202000171

## Cheminformatics in Natural Product-based Drug Discovery


Ya Chen<sup>[a]</sup> and Johannes Kirchmair<sup>\*,[a, b]</sup>

3D molecular shape-based screening, antiviral




1 (artocarpin)

Pharmacophore + shape-base, activators of the G protein-coupled bile acid receptor 1




2 (farnesiferol B)




3 (microlobidene)

Synthetic compounds with novel scaffolds



4 (rubraxanthone)


Docking,  
antiinfluenza




5 (ergosterol peroxide)

Lanostane triterpenes from the mushroom *Ganoderma lucidum*.

Pharmacophore, FXR induction /  
anti-inflammatory



6 (ganodermanontriol)




7 (truxillic acid derivative)

Gaussian process model,  
PPAR $\gamma$  activator


# De novo design of NP-inspired molecules

- Diversity-oriented synthesis (DOS)
- Biology-oriented synthesis (BIOS)
- Design of Genuine Structures (DOGS)
- Deep Neural Networks (variety of approaches)

DOGS



DNN



DOI: 10.1002/minf.202000171


**Cheminformatics in Natural Product-based Drug Discovery**

Ya Chen<sup>[a]</sup> and Johannes Kirchmair<sup>\*[a, b]</sup>



---

# Recommended chemoinformatics read




Volume 39, Issue 11

Special Issue: Molecular Informatics in Natural Products  
Research

November 2020

<https://onlinelibrary.wiley.com/toc/18681751/2020/39/11>

# HTS problems




Very high (or low) hit rates in HTS assays

- Polyphenols quench fluorescence
- Highly fluorescent or coloured compounds interfere with colorimetric or fluorescent endpoint




Enol form of curcumin



Creating and screening natural product libraries. Brice A. P. Wilson *Nat. Prod. Rep.*, 2020, 37, 893-918.

[10.1039/C9NP00068B](https://doi.org/10.1039/C9NP00068B)

# All those PAINS



Chemistry: Chemical con artists foil drug discovery. Baell & Walters. *Nature* volume 513, pages481–483 (2014)

<https://doi.org/10.1038/513481a>


Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS).

Jonathan B. Baell, *J. Nat. Prod.* 2016, 79, 3, 616–628. <https://doi.org/10.1021/acs.jnatprod.5b00947>

---

Let's imagine a promising  
bioactive NP is identified

But what about synthesis  
and scaling up?



Taxol  
(Paclitaxel)


#### News

**Tree that provides paclitaxel is put on list of endangered species**

*BMJ* 2011 ; 343 doi: <https://doi.org/10.1136/bmj.d7411> (Published 15 November 2011)




# Synthesis alone is infeasible




Taxol  
(Paclitaxel)

- Robert Holton's group suggested complete synthesis
- With ability to produce 11.6 mg of taxol



- Semi-synthesis from deacetylbaccatin extracted from European yew (Liu, Gong, Zhu, *RSC Adv*, 2016)
- 2017: 2600 kg produced

# How genomic knowledge can be used?



**1951:  
10,000 POUNDS OF PIG  
PANCREASES MAKE  
1 POUND OF INSULIN**

**TODAY:  
GENETICALLY  
ENGINEERED  
BACTERIA PRODUCE  
ANIMAL-FREE INSULIN**

**An Engineered Microbial Platform  
for Direct Biofuel Production from  
Brown Macroalgae**

Wargacki *et al.*, *Science* 2012

**High-level semi-synthetic production of the potent  
antimalarial artemisinin**

Paddon *et al.*, *Nature* 2013

**Metabolic Engineering for the  
Biosynthesis of Longevity Molecules  
Rapamycin and Resveratrol**

Ye & Bathia, *Industrial Biocatalysis* 2014


**A microbial supply chain for production of  
the anti-cancer drug vinblastine**

Zhang *et al.*, *Nature* 2022

---

# Perspectives and Sustainability

## Are we seeing a resurgence in the use of natural products for new drug discovery?

Feng Li , Yongli Wang, Dapeng Li, Yilun Chen & Q. Ping Dou

## Natural Product Research: An Immense Hope and Sustainability in Present Time

Dipankar Ghosh\*

THE LANCET



- the higher rigidity of NPs can be valuable in drug discovery tackling protein–protein interactions
  - NPs as a source of oral drugs ‘beyond Lipinski’s rule of 5’
  - Novel antibiotics able to tackle antibiotic resistance?
-

---

# Take away messages

- State-of-art analytical and computational methods give a new boost to NP-driven drug discovery
- Problems for the different discovery stages mirror each other, which might provide room for collaboration
- Interest in natural products as drug leads is being actively revitalized

Thank you for your attention!

